NAS:AKRX (USA) Also trade in: Germany

Akorn Inc

$ 4.19 0 (0%)
On watch
Volume: 898,389 Avg Vol (1m): 2,833,712
Market Cap $: 527.31 Mil Enterprise Value $: 1.16 Bil
P/E (TTM): 0.00 P/B: 1.43
Earnings Power Value 1.31
Net Current Asset Value -4.16
Tangible Book -1.32
Projected FCF 7.91
Median P/S Value 25.71
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.22
Cash-To-Debt ranked lower than
74.74% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
AKRX: 0.22
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0.3, Max: 10000
Current: 0.22
0
10000
Equity-to-Asset 0.25
Equity-to-Asset ranked lower than
79.31% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
AKRX: 0.25
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.1, Med: 0.52, Max: 0.94
Current: 0.25
0.1
0.94
Debt-to-Equity 2.25
Debt-to-Equity ranked lower than
86.41% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
AKRX: 2.25
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.53, Max: 7.46
Current: 2.25
0.01
7.46
Debt-to-EBITDA -12.27
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
AKRX: -12.27
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -15.9, Med: 1.47, Max: 7.43
Current: -12.27
-15.9
7.43
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.09
DISTRESS
GREY
SAFE
Beneish M-Score -2.81
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -12.05%
WACC 11.63%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -21.94
Operating Margin ranked lower than
76.03% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
AKRX: -21.94
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -25.71, Med: 20.86, Max: 33.26
Current: -21.94
-25.71
33.26
Net Margin % -67.38
Net Margin ranked lower than
76.93% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
AKRX: -67.38
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -57.91, Med: 14.56, Max: 31.41
Current: -67.38
-57.91
31.41
ROE % -76.04
ROE ranked lower than
75.84% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
AKRX: -76.04
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -63.04, Med: 21.2, Max: 35.12
Current: -76.04
-63.04
35.12
ROA % -27.44
ROA ranked lower than
71.30% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
AKRX: -27.44
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -33.5, Med: 8.42, Max: 24.27
Current: -27.44
-33.5
24.27
ROC (Joel Greenblatt) % -27.39
ROC (Joel Greenblatt) ranked lower than
73.80% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
AKRX: -27.39
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -48.96, Med: 54.62, Max: 86.13
Current: -27.39
-48.96
86.13
3-Year Total Revenue Growth Rate -11.00
3-Year Revenue Growth Rate ranked higher than
66.04% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
AKRX: -10.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -37.1, Med: 10, Max: 56.6
Current: -10.9
-37.1
56.6

» AKRX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AKRX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare LSE:INDV TSXV:XLY HKSE:02633 SZSE:002864 SZSE:300519 TPE:3705 TSXV:LABS XKRX:229500 XKRX:239610 XKRX:048410 XKRX:237690 TSE:4577 XKRX:293480 BSP:OFSA3 ASX:EXL XCNQ:CWEB NAS:OPTN TSX:HLS NYSE:DPLO LSE:BMK
Traded in other countries FDA.Germany
Address 1925 West Field Court, Suite 300, Lake forest, IL, USA, 60045
Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Ratios

Current vs industry vs history
PB Ratio 1.43
PB Ratio ranked lower than
58.73% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
AKRX: 1.43
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.95, Med: 5.41, Max: 16.87
Current: 1.43
0.95
16.87
PS Ratio 0.78
PS Ratio ranked higher than
50.71% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
AKRX: 0.78
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.51, Med: 4.77, Max: 11.19
Current: 0.78
0.51
11.19
EV-to-EBIT -7.86
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
AKRX: -7.86
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -64.9, Med: 17.5, Max: 213.1
Current: -7.86
-64.9
213.1
EV-to-EBITDA -17.39
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
AKRX: -17.39
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -93.5, Med: 16.6, Max: 2955.7
Current: -17.39
-93.5
2955.7
EV-to-Revenue 1.72
EV-to-Revenue ranked lower than
53.96% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
AKRX: 1.72
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.8, Med: 5.3, Max: 14.8
Current: 1.72
0.8
14.8
Shiller PE Ratio 97.99
Shiller PE Ratio ranked lower than
76.19% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
AKRX: 97.99
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 22.92, Med: 79.64, Max: 1793.67
Current: 97.99
22.92
1793.67
Current Ratio 3.26
Current Ratio ranked higher than
70.29% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
AKRX: 3.26
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.21, Med: 2.44, Max: 12.3
Current: 3.26
0.21
12.3
Quick Ratio 2.30
Quick Ratio ranked higher than
65.73% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
AKRX: 2.3
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.02, Med: 1.63, Max: 9
Current: 2.3
0.02
9
Days Inventory 145.70
Days Inventory ranked lower than
69.54% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
AKRX: 145.7
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 118.8, Med: 146.88, Max: 173.39
Current: 145.7
118.8
173.39
Days Sales Outstanding 94.15
Days Sales Outstanding ranked lower than
58.31% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
AKRX: 94.15
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 44.37, Med: 70.08, Max: 123.33
Current: 94.15
44.37
123.33
Days Payable 30.58
Days Payable ranked lower than
76.25% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
AKRX: 30.58
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 19.92, Med: 47.71, Max: 113.99
Current: 30.58
19.92
113.99

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70
3-Year Share Buyback Rate ranked higher than
57.09% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
AKRX: -1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -63.1, Med: -5.5, Max: -0.9
Current: -1.7
-63.1
-0.9

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.54
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
72.99% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
AKRX: 0.54
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.34, Med: 5.42, Max: 749
Current: 0.54
0.34
749
Price-to-Median-PS-Value 0.17
Price-to-Median-PS-Value ranked higher than
81.56% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
AKRX: 0.17
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.05, Med: 0.26, Max: 2.54
Current: 0.17
0.05
2.54
Earnings Yield (Joel Greenblatt) % -12.72
Earnings Yield (Greenblatt) ranked lower than
81.20% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
AKRX: -12.72
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -19.6, Med: 2.6, Max: 12.7
Current: -12.72
-19.6
12.7
Forward Rate of Return (Yacktman) % 16.89
Forward Rate of Return ranked higher than
97.62% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
AKRX: 16.89
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -15.5, Med: 0.3, Max: 26.4
Current: 16.89
-15.5
26.4

More Statistics

Revenue (TTM) (Mil) $ 675.83
EPS (TTM) $ -3.62
Beta 3.58
Volatility % 78.6
52-Week Range $ 2.64 - 19.65
Shares Outstanding (Mil) 125.85

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N